http://nova.newcastle.edu.au/vital/access/services/Feed ${session.getAttribute("locale")} 5 http://nova.newcastle.edu.au/vital/access/manager/Repository/uon:10606 Background: Despite a significant increase in the number of patients with paracetamol poisoning in the developing world, plasma paracetamol assays are not widely available. The purpose of this study was to assess a low-cost modified colorimetric paracetamol assay that has the potential to be performed in small laboratories with restricted resources. Methods: The paracetamol assay used in this study was based on the Glynn and Kendal colorimetric method with a few modifications to decrease the production of nitrous gas and thereby reduce infrastructure costs. Preliminary validation studies were performed using spiked aqueous samples with known concentrations of paracetamol. Subsequently, the results from the colorimetric method for 114 stored clinical samples from patients with paracetamol poisoning were compared with those from the current gold-standard high-performance liquid chromatography method. A prospective survey, assessing the clinical use of the paracetamol assay, was performed on all patients with paracetamol poisoning attending the Peradeniya General Hospital, Sri Lanka, over a 10-month period. Results: The recovery study showed an excellent correlation (r² > 0.998) for paracetamol concentrations from 25 to 400 mg/L. The final yellow color was stable for at least 10 min at room temperature. There was also excellent correlation with the high-performance liquid chromatography method (r² = 0.9758). In the clinical cohort study, use of the antidote N-acetylcysteine was avoided in over a third of patients who had the plasma paracetamol concentration measured. The cost of consumables used per assay was $0.50 (US). Conclusions: This colorimetric paracetamol assay is reliable and accurate and can be performed rapidly, easily, and economically. Use of this assay in resource-poor clinical settings has the potential to have a significant clinical and economic impact on the management of paracetamol poisoning. 2012-04-12T01:38:59.760Z ]]> http://nova.newcastle.edu.au/vital/access/manager/Repository/uon:3845 4th ed. 2010-04-27T05:32:49.868Z ]]> http://nova.newcastle.edu.au/vital/access/manager/Repository/uon:5684 Background: Bismuth iodoform paraffin paste (BIPP) is used for the packing of wound and surgical cavities. Features of both bismuth and iodoform toxicities have been associated with the use of BIPP, but there are no previous reports of 2,3-dimercaptopropane-1-sulphonate (DMPS) chelation therapy for bismuth poisoning secondary to its use. Case Report: A 67-year-old man presented with a pelvic tumor requiring extensive surgical resection. BIPP packing was required post-operatively for surgical wound breakdown. A few days after insertion, the patient developed neurological features of bismuth toxicity (blood and urine bismuth concentrations were 340 μg/L and 2800 μg/L, respectively), which was treated with removal of the BIPP packing and DMPS chelation [27 days of intravenous DMPS (5 mg/kg 4 times daily for 5 days, 5 mg/kg three times daily for 5 days followed by 5 mg/kg twice a day for 17 days) followed by 24 days of oral DMPS (200 mg three times a day for 10 days, followed 200 mg twice daily for 14 days)]. This resulted in improvement in his symptoms and a decline in his pre-chelation bismuth concentration of 480 μg/L to 5 μg/L following chelation. There were no adverse effects during chelation. Conclusions: DMPS chelation appears to be a potentially effective chelating agent in bismuth toxicity. 2010-04-27T04:50:03.416Z ]]>